Clinical Trials Directory

Trials / Conditions / Relapsed Refractory Multiple Myeloma (RRMM)

Relapsed Refractory Multiple Myeloma (RRMM)

14 registered clinical trials studyying Relapsed Refractory Multiple Myeloma (RRMM) — 13 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingBCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM
NCT07407010
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
RecruitingA Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Mu
NCT07382739
M.D. Anderson Cancer CenterPhase 2
RecruitingA Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relap
NCT07455851
Regeneron PharmaceuticalsPhase 1 / Phase 2
Not Yet RecruitingIASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
NCT07185490
Institute of Hematology & Blood Diseases Hospital, ChinaEARLY_Phase 1
Not Yet RecruitingIASO206 in Patients With Relapsed/Refractory Multiple Myeloma
NCT07322159
Institute of Hematology & Blood Diseases Hospital, ChinaEARLY_Phase 1
RecruitingMezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
NCT07032714
Massachusetts General HospitalPhase 1
RecruitingEpunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
NCT07497165
Shanxi Bethune Hospital—
Not Yet RecruitingA Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell The
NCT07185477
Institute of Hematology & Blood Diseases Hospital, ChinaEARLY_Phase 1
RecruitingPhase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
NCT06920251
Seoul National University HospitalPhase 2
RecruitingELISA in Relapsed/Refractory MM
NCT06832865
Massachusetts General HospitalPhase 2
RecruitingMezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
NCT06645678
YOUNGIL KOHPhase 1 / Phase 2
RecruitingA Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell
NCT06285318
Janssen-Cilag Ltd.—
RecruitingA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexa
NCT05730036
Regeneron PharmaceuticalsPhase 3
CompletedStudy of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Ind
NCT02649790
Karyopharm Therapeutics IncPhase 1 / Phase 2